Gritstone partners with Friends of Cancer Research on ctDNA

Gritstone bio announced that the company has joined the ctMoniTR Project, a collaborative research initiative providing foundational evidence to inform future use of change in circulating tumor DNA as an early indicator of long-term clinical benefit from therapeutics in cancer patients. The ctMoniTR Project is led by Friends of Cancer Research. “ctDNA represents a highly promising biomarker that could transform the way we develop novel cancer immunotherapies,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio. “As cancer drug development has evolved, the field has seen the immense impact that biomarkers can offer when it comes to identifying effective novel treatments early on, which can make an enormous difference in the lives of patients. We’re pleased to serve as a partner on the ctMoniTR Project, which will help empirically inform the clinical applications where ctDNA exhibits the greatest potential to accelerate novel drug development.”